NCT04869137 2026-04-08
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
H. Lee Moffitt Cancer Center and Research Institute
Dynavax Technologies Corporation
Celldex Therapeutics